Brief: Galectin Therapeutics Reports The Positive Outcome Of The Fourth Data And Safety Monitoring Board Meeting For Navigate
03/10/2023 13:28
Oct 3 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS REPORTS THE POSITIVE OUTCOME OF THE
FOURTH
DATA AND SAFETY MONITORING BOARD MEETING FOR NAVIGATE, ITS
SEAMLESS, ADAPTIVE PHASE 2B/3 STUDY OF BELAPECTIN IN PATIENTS
WITH PORTAL HYPERTENSION CAUSED BY NON-ALCOHOLIC STEATOHEPATITIS
LIVER CIRRHOSIS
* GALECTIN THERAPEUTICS INC - INTERIM TOPLINE DATA FROM
PHASE 2B
PORTION OF NAVIGATE IS EXPECTED IN Q4 OF 2024
Source text for Eikon: ID:nGNXc1P953
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study